BOSTON — The escalating use of new weight loss medications among teenagers is raising alarms about potential links to eating disorders.
GLP-1 receptor agonists, such as Wegovy, have recently been approved for adolescents aged 12 and older. Between 2020 and 2023, the number of teenagers prescribed these medications surged nearly sevenfold. Despite their effectiveness in aiding weight loss by suppressing appetite and altering metabolism, new research reveals troubling trends among young users.
A study highlighted that nearly 80% of adolescents seeking treatment for obesity also exhibited symptoms of depression and disordered eating behaviors. Mental health professionals are increasingly concerned about the risks of these drugs potentially exacerbating or triggering conditions such as binge-eating disorder or bulimia.
Experts emphasize the need for a balanced approach in obesity management that includes careful screening and monitoring for eating disorders, an aspect that is often overlooked. As these medications become more prevalent, ensuring comprehensive mental health support is crucial in addressing the broader implications of their use on adolescent well-being.
Related Topic:
Can You Lose Weight Just By Taking Keto Pills
